ClearNote Health

Great article?in The Guardian?over the weekend on a recent?large-scale UK Biobank study on how type 2 diabetes can increase risk of liver and pancreatic cancer. The study analyzed health records from? 23,750 people with newly diagnosed type 2 diabetes and compared them with more than 70,000 matched controls without diabetes. Researchers?found that the risk of pancreatic cancer was nearly twice as high in women and 74% higher in men for those recently diagnosed with the condition.? ? ?? Early detection is key.?The ClearNote Avantect test is?a simple cell-free DNA-based blood test that is designed to detect the earliest indicators of pancreatic cancer when patients are most likely to benefit from treatment. ? Read the article https://lnkd.in/ddr2HJpM?and learn more about the Avantect test on our website: https://www.avantect.com/ ? #pancreaticcancer #earlydetection

Great article in?Oncology Times?on our Avantect? Multi-Cancer Detection Test being selected as one of two blood-based technologies for the?National Cancer Institute (NCI)?Vanguard Study. This important project?will lay the groundwork for future large-scale randomized controlled trials to further validate liquid biopsy tests. Read the article here: https://lnkd.in/emTefX_u #liquidbiopsy #MCED #pancreaticcancer

We are delighted to see coverage in Clinical Lab Products regarding news that ClearNote Health’s Avantect? Pancreatic Cancer Test is now available to health plan members accessing Claritev’s national PPO networks. ?? Read the article to learn more: https://lnkd.in/dVuGTYD8 ? #pancreaticcancer #cancerearlydetection

?? We are excited to announce that ClearNote Health’s Avantect? Pancreatic Cancer Test is now available to health plan members accessing Claritev’s national PPO networks. While early detection has vastly improved survival rates for many types of cancer, #pancreaticcancer is often diagnosed at an advanced metastatic stage when patients have a five-year survival rate as low as 3%.?Avantect is an innovative DNA-based blood test that uses key epigenomic and genomic signals coupled with machine learning to detect the earliest indicators of pancreatic cancer when patients are most likely to benefit from treatment. Dave Mullarkey, CEO at ClearNote Health, comments, “We look forward to working with Claritev to enable early detection of pancreatic cancer in high-risk patients so they can live longer, healthier lives.” ?? Read the full press release on our website: https://lnkd.in/dYHkyQGS #earlycancerdetection

????Our Vice President of Laboratory Operations, Shimul Chowdhury, will be presenting a poster at?ACMG - American College of Medical Genetics and Genomics Annual Meeting, 2025. ? Title: Implementation of cfDNA Pancreatic Cancer Test in High-Risk Patients with Genetic and/or Family History of Cancer in a Clinical Setting ???When: Thursday, March 20, 10:30 am – 11:30 am PT ???Poster Number: (Odd Numbered Posters) P665 ? Pancreatic Cancer is the 3rd leading cause of cancer mortality in the U.S. and?predicted to be the 2nd-leading cause by 2030.?ClearNote Health has validated a non-invasive, blood-based, cell-free DNA (cfDNA) epigenomic early-detection pancreatic cancer test (Avantect). The poster will present the results from a recent pilot study that assessed the feasibility and integration of the test into a clinical workflow that included patients undergoing surveillance in a high-risk screening program. ? Reach out to?Shimul?to learn more about Avantect or to schedule a meeting at the event. ? #ACMG2025 #PancreaticCancer #CancerDetection

Join Us at #TRICON San Diego!??? ? Our team will be out in full force at the Precision Med TRI-CON Conference, March 11-13 - come and visit us at booth #3. ? Discover how our Virtuoso Epigenomics Platform is empowering more efficient oncology drug discovery and development by leveraging 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma. ? ????Plus, don't miss the talk from our Chief Scientific Officer, Samuel Levy: Title:?Epigenomic Liquid Biopsy Tools for Individualized Signals of Therapy Response When: Tuesday, March 11, 2025, 2:25 – 2:55 PM Track: Liquid Biopsy ? Reach out to schedule a meeting: [email protected] ? #LiquidBiopsy #Cancer #Epigenomics #Oncology

?? Press Release: ClearNote Health today announced that the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved its Avantect? Pancreatic Cancer Test. With this approval, clinicians in New York State can now order this highly sensitive blood test, which is designed to detect the biological signals of pancreatic cancer in its earliest stages for patients with known risk factors. “New York State is well known for its rigorous, patient-focused quality standards for laboratory-developed tests. This approval is another critical milestone for ClearNote Health, further validating our ongoing commitment to excellence in our tests and in our clinical laboratory services,” said Dave Mullarkey, CEO at ClearNote Health. ?? Read the full press release here: https://lnkd.in/dcbybtiu #earlycancerdetection #pancreaticcancer

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, and Senior Scientist-Translational Research, Ceyda Coruh, are attending the 9th Liquid Biopsy for Precision Oncology Summit February 18-20, San Diego. Connect to learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient oncology drug discovery and development. #drugdiscovery #drugdevelopment #oncology #cfDNA #liquidbiopsy #CDx

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) #GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient oncology drug discovery and development. #drugdiscovery #drugdevelopment #oncology #cfDNA #liquidbiopsy

????Celebrating International Day of Women and Girls in Science!??????? ? Today, we recognize the incredible contributions of women and girls in STEM fields and celebrate those who continue to break barriers, drive innovation, and inspire future generations.???? ? Tag a woman in STEM who inspires you or share a favorite achievement by women in science! #WomenInScience #STEM #DiversityInSTEM